Your Complete Guide to Wegovy, Mounjaro & Ozempic Options
Understanding Prescription Weight Loss: Wegovy vs Mounjaro vs Ozempic Mechanisms
When comparing Wegovy, Mounjaro, and Ozempic for weight management, understanding their different mechanisms is crucial for making an informed choice. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone, whilst Mounjaro (tirzepatide) offers dual action by targeting both GLP-1 and GIP receptors. This dual mechanism may provide additional metabolic benefits, though both treatments work by reducing appetite and promoting satiety after smaller meals.
Ozempic, whilst containing the same semaglutide as Wegovy, is licensed specifically for type 2 diabetes management in the UK. Only Wegovy and Mounjaro hold MHRA licensing for weight management in adults with BMI ≥30, or BMI ≥27 with weight-related comorbidities. Both prescription-only medicines require clinical assessment and must be used alongside a reduced-calorie diet and increased physical activity for optimal results.
Wegovy vs Mounjaro vs Ozempic Pricing: Transparent UK Costs
EverydayMeds offers competitive pricing across our weight management portfolio, with Wegovy starting at £79.99 for the 0.25mg starter dose after applying discount code FIRST40 at checkout. Our tiered pricing reflects the dose escalation protocol, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the maintenance 2.4mg dose. Returning customers can access ongoing savings with code DOSE25 applied at checkout.
Mounjaro follows a different pricing structure due to its unique dual-action formulation, with costs varying by prescribed dose strength. Both treatments offer convenient bundle options for continuous supply, such as our Intro Duo (0.25mg & 0.5mg Wegovy) for £169.99, providing seamless progression through initial dose escalation phases. All prices include prescriber review, with express 24-hour assessment available for urgent requirements.
Clinical Evidence: Wegovy and Mounjaro Weight Loss Trial Data
In clinical trials, patients taking Wegovy alongside diet and exercise demonstrated significant weight management outcomes across the STEP trial programme. STEP 1 showed approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo, whilst STEP 5 demonstrated 15.2% sustained weight loss at 2 years. The SELECT cardiovascular outcomes trial revealed a 20% reduction in major cardiovascular events (HR 0.80).
Mounjaro's SURMOUNT trials demonstrated substantial weight management results through its dual GIP+GLP-1 mechanism, though direct comparison between Wegovy and Mounjaro trial outcomes isn't appropriate due to different study designs and patient populations. Both treatments require individual clinical assessment to determine suitability, as trial results may not reflect individual outcomes.
How Wegovy Works for Prescription Weight Loss Management
Wegovy functions as a GLP-1 receptor agonist, mimicking your body's natural incretin hormone that regulates blood sugar and appetite. Once injected weekly using the FlexTouch pen device, semaglutide activates GLP-1 receptors in your brain's appetite centres, potentially reducing food cravings and promoting feelings of fullness after smaller meals. This mechanism may help patients naturally consume fewer calories without the constant hunger experienced with traditional calorie restriction. The treatment works progressively through mandatory dose escalation from 0.25mg to 2.4mg over 16 weeks, allowing your body to adapt gradually. Clinical effectiveness requires combination with lifestyle modifications including reduced-calorie diet and increased physical activity. Individual responses vary, and some patients may experience side effects during the initial weeks as their system adjusts to the medication.
Streamlined Ordering Process for Wegovy, Mounjaro, and Ozempic
Starting your prescription weight loss journey begins with our 3-minute online clinical assessment, designed to capture essential medical history and current health status efficiently. Our UK-registered prescribers review each application within standard 3 working days, or 24 hours with express service, ensuring thorough clinical evaluation before approval. Upon prescription approval, your chosen treatment ships via next-day delivery using temperature-controlled cold-chain logistics to maintain medication integrity. Our GPhC-registered pharmacy (#9012878) handles all aspects from clinical review to doorstep delivery, eliminating multiple provider coordination. Payment processing occurs after prescriber approval, with discount codes FIRST40 (new customers) or DOSE25 (returning customers) applied automatically at checkout. Ongoing support includes dose escalation guidance and repeat prescription management through your patient portal.
Storage and Practical Considerations: Wegovy vs Mounjaro vs Ozempic
Storage requirements differ significantly between treatments, with Wegovy offering superior convenience for travel and daily life management. Wegovy pens maintain stability for 6 weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. Both require initial refrigeration at 2-8°C before first use, but Wegovy's extended ambient storage provides flexibility for business travel, holidays, or simply forgetting to refrigerate immediately. The FlexTouch pen device delivers consistent dosing with a simple once-weekly injection, typically into your thigh, upper arm, or abdomen. Dose escalation follows a strict protocol that cannot be accelerated, ensuring tolerability and effectiveness. Most patients find the injection process straightforward after initial guidance, with needle anxiety typically diminishing within the first few administrations.
Choosing Between Wegovy, Mounjaro, and Ozempic for Weight Management
The decision between Wegovy and Mounjaro for prescription weight loss depends on individual clinical factors rather than universal superiority of either treatment. Your prescriber will consider your medical history, current medications, previous weight management attempts, and specific health goals when recommending the most appropriate option. Some patients may respond better to Wegovy's established GLP-1 mechanism, whilst others might benefit from Mounjaro's dual-action approach.
Ozempic, despite containing the same semaglutide as Wegovy, remains licensed exclusively for type 2 diabetes management and should not be considered for weight loss unless you have concurrent diabetes requiring treatment. Both Wegovy and Mounjaro are available through EverydayMeds with the same rigorous clinical assessment process, and your prescriber can help determine which treatment aligns with your individual circumstances and health objectives.
Begin Your Prescription Weight Loss Journey Today
Taking the first step towards prescription weight loss with Wegovy, Mounjaro, or appropriate diabetes management with Ozempic starts with completing our comprehensive clinical assessment at https://everydaymeds.co.uk/collections/wegovy. New customers benefit from discount code FIRST40, whilst returning patients can use DOSE25 for ongoing savings applied at checkout. Our prescribers provide detailed treatment guidance, dose escalation support, and ongoing monitoring throughout your weight management journey. Remember that sustainable weight management requires commitment to lifestyle changes alongside prescription treatment, and individual results may vary. Don't wait to explore your options – complete your assessment today and discover which prescription-only medicine might support your health goals. This prescription weight loss comparison guide has been reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
